Brain Glucocerebrosidase in Gaucher's Disease
Overview
Authors
Affiliations
Using glucocerebroside labeled with carbon 14 as the substrate, we determined that homogenates of brain tissue from both neuropathic and nonneuropathic cases of Gaucher's disease were profoundly deficient (more than 85%) in glucocerebrosidase activity. The beta-glucosidase activity, as measured with 4-methylumbelliferyl-beta-D-glucopyranoside as the substrate, in the homogenates of brain from four cases of Gaucher's disease was less sensitive to inhibition by conduritol B epoxide (CBE) when compared with normal brain beta-glucosidase. However, when homogenates were assayed with radiolabeled glucocerebroside as the substrate, no differential sensitivity toward CBE was indicated, suggesting the presence of an additional, CBE-insensitive, beta-glucosidase in brain tissue. Residual glucocerebrosidase activity partially purified from the brain of an adult with type 1 Gaucher's disease was activated threefold by gluconoyl hydrazine, whereas the same enzyme from control brain was unaffected, and eight times less sensitive to gluconolactone inhibition.
Hulkova H, Ledvinova J, Poupetova H, Kohout A, Malinova V, Elleder M J Inherit Metab Dis. 2009; 32(4):551-9.
PMID: 19557545 DOI: 10.1007/s10545-009-1178-9.
Xu Y, Reboulet R, Quinn B, Huelsken J, Witte D, Grabowski G Mol Genet Metab. 2008; 94(2):190-203.
PMID: 18346921 PMC: 2577881. DOI: 10.1016/j.ymgme.2008.01.013.
Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.
Xu Y, Quinn B, Witte D, Grabowski G Am J Pathol. 2003; 163(5):2093-101.
PMID: 14578207 PMC: 1892407. DOI: 10.1016/s0002-9440(10)63566-3.
Treatment of Gaucher disease with an enzyme inhibitor.
RADIN N Glycoconj J. 1996; 13(2):153-7.
PMID: 8737239 DOI: 10.1007/BF00731489.
Characterization of the phospholipid requirement of a rat liver beta-glucosidase.
Basu A, Glew R Biochem J. 1984; 224(2):515-24.
PMID: 6517862 PMC: 1144460. DOI: 10.1042/bj2240515.